Related Experiment Video

Updated: Aug 11, 2026

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix
10:21

Scanning Electron Microscopy of Macerated Tissue to Visualize the Extracellular Matrix

Published on: June 14, 2016

Survival and prognostic factors in hypertrophic cardiomyopathy: a meta-analysis

Qun Liu1, Diandian Li1,2, Alan E Berger1

  • 1Division of Allergy & Clinical Immunology, Johns Hopkins University School of Medicine, Baltimore, MD, 21224, USA.

Scientific Reports
|September 22, 2017
PubMed

Insights

This meta-analysis reveals survival rates for hypertrophic cardiomyopathy (HCM) patients are high, with key factors like non-sustained ventricular tachycardia (nsVT) and obstruction predicting cardiovascular death. Early identification of these risk factors is crucial for timely interventions.

Area of Science:

  • Cardiology
  • Genetics
  • Clinical Medicine

Background:

  • Hypertrophic cardiomyopathy (HCM) is a complex genetic disorder with variable clinical presentations.
  • Existing data on survival rates and prognostic factors in HCM patients are conflicting and lack comprehensive review.

Purpose of the Study:

  • To perform a meta-analysis of cohort studies to determine pooled survival rates in HCM patients.
  • To identify significant prognostic factors associated with survival in individuals diagnosed with HCM.

Main Methods:

  • A meta-analysis was conducted, synthesizing data from nineteen cohort studies.
  • The analysis included a total of 12,146 patients diagnosed with hypertrophic cardiomyopathy.

Main Results:

  • Pooled survival rates at 1, 3, 5, and 10 years were 98.0%, 94.3%, 82.2%, and 75.0%, respectively.
  • Significant prognostic factors for cardiovascular death included age, NYHA class, family history of sudden death (FHSD), syncope, atrial fibrillation, non-sustained ventricular tachycardia (nsVT), maximum left ventricular wall thickness, and obstruction.
  • Non-sustained ventricular tachycardia (nsVT) and left ventricular outflow tract obstruction/mid-ventricular obstruction (LVO/MVO) were identified as the strongest predictors for cardiovascular and all-cause/sudden cardiac death, respectively.

Conclusions:

  • Survival rates in HCM patients are generally high, but specific risk factors significantly impact outcomes.
  • Identifying patients at higher risk through factors like nsVT and obstruction is critical for targeted therapeutic interventions.
  • These findings can guide early diagnosis and management strategies to improve long-term survival in hypertrophic cardiomyopathy.

More Related Videos

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level06:02

An Approach to Study Shape-Dependent Transcriptomics at a Single Cell Level

Published on: November 2, 2020

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model03:45

Investigating the Pathogenesis of MYH7 Mutation Gly823Glu in Familial Hypertrophic Cardiomyopathy using a Mouse Model

Published on: August 8, 2022

Related Concept Videos

Pathophysiology of Heart Failure01:17

Pathophysiology of Heart Failure

Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...